The art of prescribing trastuzumab for HER2-positive breast cancer
Keywords: Her-2 positive breast cancer, trastuzumab, patient eligibility, tolerability, dosing regimens, resistance
AbstractThe human epidermal growth factor receptor 2 (HER2) is overexpressed in HER2-positive breast cancer. This confers characteristics associated with an overall poor prognosis, with early metastases to major visceral sites and a relative resistance to chemotherapy. Trastuzumab is a humanised monoclonal therapeutic antibody that specifically targets HER2 receptor overexpressing breast cancer cells, inhibiting their growth and proliferation, and inducing their regression. It is licensed for metastatic and early HER2-positive breast cancer, determined by slidebased testing techniques. Trastuzumab dosing regimens are aimed at increasing its efficacy, while minimising its potentially undesirable effects which include cardiotoxicity and the development of resistance.
By submitting manuscripts to SAJGO, authors of original articles are assigning copyright to the South African Society of Gynaecologic Oncology (SASGO). Authors may use their own work after publication without written permission, provided they acknowledge the original source. Individuals and academic institutions may freely copy and distribute articles published in SAJGO for educational and research purposes without obtaining permission.